NewAmsterdam Pharma Announces Inducement Grants in Compliance with Nasdaq Listing Rule 5635(c)(4)

Inducement Share Options Granted: NewAmsterdam Pharma's Compensation Committee approved the grant of 18,000 share options to a new non-executive hire as part of the 2024 Inducement Plan, with an exercise price of $37.00 per share.

Vesting Schedule: The share options will vest over four years, with 25% vesting on the one-year anniversary and the remainder in 36 equal monthly installments, contingent on the employee's continued service.

Company Overview: NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, non-statin therapies for patients at risk of cardiovascular disease, particularly those with elevated LDL cholesterol levels.

Ongoing Research: The company is conducting phase 3 studies on obicetrapib, a CETP inhibitor, as a potential LDL-C lowering therapy, either alone or in combination with ezetimibe, for patients who do not respond well to existing treatments.